Related Experiment Video
Updated: Sep 5, 2025

Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack
Published on: May 15, 2020
Clozapine treatment and risk of COVID-19
Emanuele F Osimo1, Jonathan Lewis2, Rudolf N Cardinal3
1Institute of Clinical Sciences, Faculty of Medicine, Imperial College Institute of Clinical Sciences and MRC London Institute of Medical Sciences, Hammersmith Hospital Campus, London, UK; Department of Psychiatry, University of Cambridge, UK; Adult Mental Health directorate, Cambridgeshire and Peterborough NHS Foundation Trust, Cambridge, UK; and South London and Maudsley NHS Foundation Trust, UK.
Abstract:
The antipsychotic clozapine is known to have immune-modulating effects. Clozapine treatment has been reported to be associated with increased risk of COVID-19 infection. However, it remains unclear whether this is because of increased testing of this patient group, who are closely monitored. We linked anonymised health records from mental health services in Cambridgeshire (UK), for patients taking antipsychotic medication, with data from the local COVID-19 testing hub. Patients receiving clozapine were more likely to be tested for COVID-19, but not to test positive. Increased testing in patients receiving clozapine suggests prudent judgement by clinicians, considering the overall health vulnerabilities of this group.
Related Concept Videos
Psychosis: Goals of Pharmacotherapy
Psychosis and Antipsychotic Drugs: Overview
Drug Therapy
Antianxiety Medications
Antipsychotic Drugs: Typical and Atypical Agents
Psychological and Sociocultural Causes of Schizophrenia
Antipsychotic Drugs: Therapeutic Uses and Side Effects
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...

